Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AME Study of [14C]-TNP-2092 in Healthy Men
NCT05074134Phase 1Completed
- Sponsor
- TenNor Therapeutics
- Start
- Oct 2021
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rifaquizinone in prosthetic joint infection (PJI) and acute bacterial skin and skin structure infection (ABSSSI), sponsored by TenNor Therapeutics. Primary endpoints: Mass balance of TNP-2092 and percentages of radiolabel recovered at Day 7 and Pharmacokinetics of TNP-2092 in plasma at Day 7. Started Oct 2021; status: completed.
02
Drugs
rifaquizinone
03
Conditions
prosthetic joint infection (PJI)acute bacterial skin and skin structure infection (ABSSSI)
Beyond the preview
Go deeper on NCT05074134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05074134.